Marc Righini

University Hospital of Geneva
Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (17)

Year:

2025

Year:

2025

Summary: Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in ultrasound series and is a frequent medical condition, which management is not well established. Data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated. This data had some impact on international recommendations like the American College of Chest Physicians (ACCP), whose last version stated that ultrasound surveillance might be an option for selected low-risk patients. However, robust data arising from randomized studies are scarce. Indeed, only seven randomized trials assessing the need for anticoagulation for calf DVT have been published. Many of these trials had an open-label design and were affected by methodological limitations. When considering randomized placebo-controlled trials, one included low-risk patients and was hampered by a limited statistical power (CACTUS study). Nevertheless, data from this trial tend to confirm that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE but is associated with a higher risk of bleeding. A second randomized placebo-controlled trial did not assess the necessity of anticoagulant treatment but rather the long-term risk of recurrence and compared 6 weeks versus 12 weeks of treatment with rivaroxaban (RIDTS study). Finally, the last available randomized trial compared a 3-month versus a 12-month edoxaban treatment in patients with cancer and mainly asymptomatic distal DVT, detected by systematic compression ultrasonography. Overall, available data suggest that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE. High risk patients (previous VTE, active cancer, inpatients) might benefit from a course of anticoagulant treatment. However, the optimal anticoagulant intensity and duration are uncertain and further studies are needed.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Jonas Spaak

Clinical Professor, Head of Research, Dept Cardiology

Karolinska Institutet

SWEDEN
View details

Aleš Blinc

-

SLOVENIA
View details

Isabelle Mahé

Université Paris Cité

FRANCE
View details

Anastasios Kollias

Professor of Medicine

National and Kapodistrian University of Athens - Faculty of Medicine

GREECE
View details

Helia Robert-Ebadi

-

SWITZERLAND
View details

Davide Voci

University Hospital of Zurich

SWITZERLAND
View details

Frederikus A. Klok

Leiden University Medical Center

NETHERLANDS
View details

Stefano Lanzi

Lausanne University Hospital

SWITZERLAND
View details

Alessandra Bura‐Rivière

Toulouse University Hospital

FRANCE
View details

Aurélien Delluc

University of Ottawa

CANADA
View details

Peter Marschang

Medical University of Innsbruck

AUSTRIA
View details

Grégoire Le Gal

University of Ottawa

CANADA
View details

MARIA CATALANO

University of Milan

ITALY
View details

Grigoris Gerotziafas

Sorbonne Université

FRANCE
View details

Borislava Mihaylova

Professor of Health Economics

Queen Mary University of London

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.